Advertisement

Massive Perivillous Fibrinoid Deposition and Maternal Floor Infarct

  • Philip J. Katzman
  • Linda M. Ernst
  • Irene B. Scheimberg
Chapter

Abstract

Massive perivillous fibrinoid deposition (MPVFD) and maternal floor infarct (MFI) are part of a spectrum of lesion in which fibrinoid material is laid down between chorionic villi. These lesions can be recurrent and are associated with fetal growth restriction and, when severe, intrauterine fetal demise.

Keywords

Chorionic villus Fetal growth restriction Fibrin Infarction Recurrence Thrombus 

References

  1. 1.
    Nelson DM, Crouch EC, Curran EM, Farmer DR. Trophoblast interaction with fibrin matrix: epithelialization of perivillous fibrin deposits as a mechanism for villous repair in the human placenta. Am J Pathol. 1990;136:855–65.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Vernof KK, Benirschke K, Gail M, et al. Maternal floor infarction: relationship to X-cells, major basic protein and adverse perinatal outcome. Am J Obstet Gynecol. 1992;167:1355–63.CrossRefGoogle Scholar
  3. 3.
    Katzman PJ, Genest DR. Maternal floor infarction and massive perivillous fibrin deposition: histological definitions, association with intrauterine fetal growth restriction, and risk or recurrence. Pediatr Dev Pathol. 2002;5:159–64. Erratum 2002;6:102CrossRefGoogle Scholar
  4. 4.
    Naeye RL. Maternal floor infarction. Hum Pathol. 1985;16:823–8.CrossRefGoogle Scholar
  5. 5.
    Andres RL, Kuyper W, Resnik R, et al. The association of maternal floor infarction of the placenta with adverse perinatal outcome. Am J Obstet Gynecol. 1990;163:935–8.CrossRefGoogle Scholar
  6. 6.
    Bane AL, Gillan JE. Massive perivillous fibrinoid causing recurrent placental failure. BJOG. 2003;110:292–5.CrossRefGoogle Scholar
  7. 7.
    Fuke Y, Aono T, Imai S, et al. Clinical significance and treatment of massive intervillous fibrin deposition associated with recurrent fetal growth retardation. Gynecol Obstet Investig. 1994;38:5–9.CrossRefGoogle Scholar
  8. 8.
    Faye-Petersen OM, Ernst LM. Maternal floor infarction and massive perivillous fibrin deposition. Surg Pathol Clin. 2013;6:101–14.CrossRefGoogle Scholar
  9. 9.
    Yu W, Tellier R, Wright JR Jr. Coxsackie virus A16 infection of placenta with massive perivillous fibrin deposition leading to intrauterine fetal demise at 36 weeks gestation. Pediatr Dev Pathol. 2015;18:331–4.CrossRefGoogle Scholar
  10. 10.
    Ordi J, Ismail MR, Ventura PJ, et al. Massive chronic intervillositis of the placenta associated with malaria infection. Am J Surg Pathol. 1998;22:1006–11.CrossRefGoogle Scholar
  11. 11.
    Bendon RW, Hommel AB. Maternal floor infarction in autoimmune disease: two cases. Pediatr Pathol Lab Med. 1996;16:293–7.CrossRefGoogle Scholar
  12. 12.
    Katz VL, Bowes WA Jr, Sierkh AE. Maternal floor infarction of the placenta associated with elevated second trimester maternal serum feto-protein. Am J Perinatol. 1987;4:225–8.CrossRefGoogle Scholar
  13. 13.
    Uxa R, Baczyk D, Kingdom JCP, et al. Genetic polymorphisms in the fibrinolytic system of placentas with massive perivillous fibrin deposition. Placenta. 2010;31:499–505.CrossRefGoogle Scholar
  14. 14.
    Pediatr Pathol Devisme L, Chauvière C, Franquet-Ansart H, et al. Perinatal outcome of placental massive perivillous fibrin deposition: a case-control study. Prenat Diagn. 2017;37:323–8.CrossRefGoogle Scholar
  15. 15.
    Griffin AC, Strauss AW, Bennett MJ, Ernst LM. Mutations in long-chain 3-hydroxyacyl coenzyme a dehydrogenase are associated with placental maternal floor infarction/massive perivillous fibrin deposition. Pediatr Dev Pathol. 2012;15:368–74.CrossRefGoogle Scholar
  16. 16.
    Sebire NJ, Backos M, Goldin RD, Regan L. Placental massive perivillous fibrin deposition associated with antiphospholipid antibody syndrome. Br J Obstet Gynaecol. 2002;109:570–3.CrossRefGoogle Scholar
  17. 17.
    Matern D, Schehata BM, Shekhawa P, et al. Placental floor infarction complicating the pregnancy of a fetus with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. Mol Genet Metab. 2001;72:265–8.CrossRefGoogle Scholar
  18. 18.
    Whitten AE, Romero R, Korzeniewski SJ, et al. Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. Am J Obstet Gynecol. 2013;208:310.e1–310.e11.CrossRefGoogle Scholar
  19. 19.
    Linn RL, Kiley J, Minturn L, et al. Recurrent massive perivillous fibrin deposition in the placenta associated with fetal renal tubular dysgenesis: case report and literature review. Pediatr Dev Pathol. 2013;16:378–86.CrossRefGoogle Scholar
  20. 20.
    Romero R, Whitten A, Korzeniewski SJ, et al. Maternal floor infarction/massive perivillous fibrin deposition: a manifestation of maternal antifetal rejection. Am J Reprod Immunol. 2013;70:285–98.CrossRefGoogle Scholar
  21. 21.
    Adams-Chapman I, Vaucher YE, Bejar RF, et al. Maternal floor infarction of the placenta: association with central nervous system injury and adverse neurodevelopmental outcome. J Perinatol. 2002;22:236.CrossRefGoogle Scholar
  22. 22.
    Benirschke K, Driscoll SG. The pathology of the human placenta. New York: Springer-Verlag; 1967.Google Scholar
  23. 23.
    Abdulghani S, Moretti F, Gruslin A, Grynspan D. Recurrent massive perivillous fibrin deposition and chronic intervillositis treated with heparin and intravenous immunoglobulin: a case report. J Obstet Gynaecol Can. 2017;39:676–81.CrossRefGoogle Scholar
  24. 24.
    Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). J Matern Fetal Neonatal Med. 2016;29:855–62.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Philip J. Katzman
    • 1
  • Linda M. Ernst
    • 2
    • 3
  • Irene B. Scheimberg
    • 4
    • 5
  1. 1.Department of Pathology and Laboratory MedicineUniversity of Rochester Medical CenterRochesterUSA
  2. 2.NorthShore University Healthsystem, Evanston HospitalEvanstonUSA
  3. 3.The University of Chicago Pritzker School of MedicineChicagoUSA
  4. 4.Queen Mary University College Medical SchoolLondonUK
  5. 5.Department of Cellular PathologyThe Royal London Hospital, Barts Health NHS TrustLondonUK

Personalised recommendations